

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/083,565	02/27/2002	Chin-Wen Chi	03806.0532	5910
75	590 01/09/2003			
Finnegan, Henderson, Farabow,			EXAMINER	
Garrett & Dunn 1300 I Street, N	I.W.		GOLDBERG, JEROME D	
Washington, DC 20005-3315			ART UNIT	PAPER NUMBER
			1614	
		•	DATE MAILED: 01/09/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Amilianda				
	Application No.	Applicant(s)				
Office Action Summans	10/083,565	CHI ET AL.				
Office Action Summary	Examiner	Art Unit				
TI MAII INO DATE Afabi a constitution	Jerome D Goldberg	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)⊠ Responsive to communication(s) filed on <u>15 October 2002</u> .						
2a)⊠ This action is FINAL . 2b)□ Thi	is action is non-final.	•				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 7-9 and 12-22 is/are pending in the application.						
4a) Of the above claim(s) <u>13-15</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) 7-9,12 and 16-22 is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement. Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
 a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 9	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 10/083,565

Art Unit: 1614

Claims 13-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 6.

This application contains claims 13-15 are drawn to an invention nonelected with traverse in Paper No. 6. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negative by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 7-9, 12, and 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over the Broder et al, patent of record for the reasons fully set forth in paper no. 7, pages 2 and 3. Applicants' remarks are noted. Applicants state, "Broder et

Application/Control Number: 10/083,565

Art Unit: 1614

al. does not disclose or suggest that such intravenous and oral administration of docetaxel can be used to treat hepatocellular carcinoma," (page 4, lines 21 and 22 of paper no. 8) Broder et al states in col. 13, lines 29-32 that "among the types of carcinoma which may be treated effectively with oral paclitaxol, docetaxol, other taxones and their prodrugs and derivatives are hepatocellular carcinoma". And on lines 55-59 state that "method of the invention, in selectively producing high blood concentrations of antitumor agents is particularly valuable in the treatment of liver cancer including, e.g. hepatocellular carcinoma and liver metastases". It is clear from the above that docetaxol could be useful in the treatment of hepatocellular carcinomas. Clearly a side-by-side comparison of the oral administration is the intravenous administration is needed.

With regard to the other agents being employed in the Broder et al. patent, the instant claims are directed to "comprising" which would include the additional agents.

Moreover, the Broder et al. claims (A col. 27 and 28) are directed to "hepatocellular carcinoma and liver cancer (claim 36).

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday- Thursday 9 am - 3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-4556 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

JEROME D. GOLDBERG PRIMARY EXAMINER

Goldberg/T.G.D. January 8, 2003